BFRI Biofrontera Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
What changed
Recent filings, trades and movesA blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 1.23 |
| Cost of Equity (CAPM) | 11.32% |
| WACC | 8.74% |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 2526.3% |
| Book / Price | -2.7% |
| Gross Margin (TTM) | 79.6% |
| FCF Margin (TTM) | -11.5% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $0.98 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $0.83 |
| Bollinger Width / SMA20 | 49.0% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 46.2× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 24.8× · 7 peers |
| Peer P/B | n/a | 0% | median 8.1× · 6 peers |
| Peer P/S | $21.63 | 19% | median 6.8× · 7 peers |
| Market Anchor (SMA50) | $0.98 | 81% | stability 64% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |

- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 94
- List Date
- 2021-10-29
- CIK
- 0001858685
- Last Earnings
- Aug 13
- Headquarters
- Woburn, MA
- Homepage
- https://www.biofrontera-us.com
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -51.01% | 0.56% | -52.50% | 3.67% | 28.32% | -14.19% |
| Feb | -- | -31.40% | -14.01% | -37.25% | -12.92% | 1.74% | -18.77% |
| Mar | -- | 17.67% | -12.93% | 72.65% | -8.05% | -12.46% | 11.38% |
| Apr | -- | 5.41% | -6.08% | -4.17% | -12.39% | 17.28% | 0.01% |
| May | -- | -24.27% | -18.02% | -47.45% | -18.56% | -17.96% | -25.25% |
| Jun | -- | -32.12% | 11.83% | -12.82% | 24.43% | -0.91% | -1.92% |
| Jul | -- | -20.56% | 8.70% | 34.52% | 56.98% | 19.38% | 19.80% |
| Aug | -- | -24.18% | -26.98% | -3.56% | -14.80% | 28.57% | -8.19% |
| Sep | -- | -9.48% | 2.81% | 12.71% | 17.26% | -29.64% | -1.27% |
| Oct | 0.00% | 2.86% | -46.22% | 4.24% | 7.84% | -16.07% | -7.89% |
| Nov | 44.69% | -1.87% | -31.29% | -17.43% | -25.74% | -31.07%* | -10.45% |
| Dec | 73.67% | -12.78% | -26.13% | 9.00% | -29.71% | -- | 2.81% |
| Total | 151.28% | -89.71% | -85.56% | -69.01% | -34.94% | -31.92% | -26.64% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-07-12 | unknown | 4.80% | 5.56% | 1.16x | Exceeded |
| 2023-03-08 | unknown | 16.80% | 10.24% | 0.61x | Within |
| 2023-07-13 | unknown | 372.73% | 4.04% | 0.01x | Within |
| 2023-10-04 | unknown | 353.85% | 0.47% | 0.00x | Within |
| 2024-01-11 | unknown | 1230.00% | 3.49% | 0.00x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BFRI Options Activity & IV Rank
Volatility Metrics
Options Flow · One expiry
ATM Options Pricing
Chain Summary
BFRI Implied Volatility
Loading implied volatility…
The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much BFRI actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $714K | #2480 of 3151 | +319.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $99K | #5808 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BFRI Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
BFRI Insider Trading (Form 4)
Latest: 2026-07-29| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | Hermann Luebbert | CEO & Chairman | Exer (M) | +62,500 | — | EDGAR | |
| 2026-07-29 | Eugene Frederick Leffler | Chief Financial Officer | Exer (M) | +31,250 | — | EDGAR |
BFRI Insider Holdings
2 insiders · @ $0.58| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Hermann Luebbert | CEO & Chairman | 352,711 | $206.2K | $0 | 1 | 2026-07-29 |
| 2 | Eugene Frederick Leffler | Chief Financial Officer | 206,250 | $120.6K | $0 | 1 | 2026-07-29 |
BFRI Board & Officers
As of SEC filings through Jul 29, 2026Directors 7
- Hermann Luebbert · since Oct 28, 2021
- Beth J. Hoffman · since Nov 2, 2021
- John J Borer III · since Nov 2, 2021
- Kevin Daniel Weber · since Mar 2, 2022
- Heikki Lanckriet · since Jul 3, 2023
- Biofrontera AG (entity) · listed since Jul 2025
- Huerta Martinez Maria del Pilar de la · since Sep 16, 2025
Officers 3
- Hermann Luebbert · CEO & Chairman · listed since Jul 2024
- Eugene Frederick Leffler · Chief Financial Officer · since Oct 24, 2022
- George Patrick Jones · Chief Commercial Officer · since Aug 25, 2025
10% owners 8
- Balaton Aktiengesellschaft Deutsche · since Sep 16, 2025
- Beteiligungen Aktiengesellschaft VV · since Sep 16, 2025
- Biofrontera AG (entity) · since Oct 28, 2021
- Christian Alexander Ansgar Link · since Sep 16, 2025
- Hansjoerg Plaggemars · since Sep 16, 2025
- Huerta Martinez Maria del Pilar de la · since Sep 16, 2025
- Unternehmensberatung Aktiengesellschaft Delphi · since Sep 16, 2025
- Wilhelm Konrad Thomas Zours · since Sep 16, 2025
Changes in the last 10 years (29)
| Sep 16, 2025 | Wilhelm Konrad Thomas Zours became a 10% owner |
| Sep 16, 2025 | Unternehmensberatung Aktiengesellschaft Delphi became a 10% owner |
| Sep 16, 2025 | Huerta Martinez Maria del Pilar de la became a director |
| Sep 16, 2025 | Huerta Martinez Maria del Pilar de la became a 10% owner |
| Sep 16, 2025 | Hansjoerg Plaggemars became a 10% owner |
| Sep 16, 2025 | Christian Alexander Ansgar Link became a 10% owner |
| Sep 16, 2025 | Beteiligungen Aktiengesellschaft VV became a 10% owner |
| Sep 16, 2025 | Balaton Aktiengesellschaft Deutsche became a 10% owner |
| Aug 25, 2025 | George Patrick Jones became Chief Commercial Officer |
| Jul 9, 2025 | Biofrontera AG first listed as a director in an SEC filing |
| Jul 16, 2024 | Hermann Luebbert listed as CEO & Chairman (previously Executive Chairman) in SEC filings |
| Jul 3, 2023 | Heikki Lanckriet became a director |
| May 22, 2023 | The company announced the departure of Loretta M. Wedge from the board in an SEC filing |
| May 8, 2023 | The company announced the departure of Erica L. Monaco as Chief Executive Officer in an SEC filing |
| Jan 12, 2023 | Erica F. Gates reported in an SEC filing no longer being Controller |
| Oct 24, 2022 | Eugene Frederick Leffler became Chief Financial Officer |
| Mar 2, 2022 | Kevin Daniel Weber became a director |
| Jan 19, 2022 | Hermann Luebbert listed as Executive Chairman (previously Chief Executive Officer) in SEC filings |
| Dec 13, 2021 | Erica L. Monaco listed as Chief Executive Officer (previously Chief Financial Officer/COO) in SEC filings |
| Nov 3, 2021 | The company announced the departure of Erica L. Monaco from the board in an SEC filing |
| Nov 2, 2021 | Loretta M. Wedge became a director |
| Nov 2, 2021 | John J Borer III became a director |
| Nov 2, 2021 | Beth J. Hoffman became a director |
| Oct 28, 2021 | Hermann Luebbert became a director |
| Oct 28, 2021 | Hermann Luebbert became Chief Executive Officer |
| Oct 28, 2021 | Erica L. Monaco became a director |
| Oct 28, 2021 | Erica L. Monaco became Chief Financial Officer/COO |
| Oct 28, 2021 | Erica F. Gates became Controller |
| Oct 28, 2021 | Biofrontera AG became a 10% owner |
- Prev
- 1
| Filing Date | Accession | Link |
|---|
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $74,092 | — | 2026-10-31 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $9.07M | $-6.42M | $-0.42 | $-1.43M |
| Q2 '26 | 2026-06-30 | $12.00M | $-604.00K | $-0.05 | $-1.66M |
| Q1 '26 | 2026-03-31 | $10.08M | $-4.75M | $-0.41 | $-70.00K |
| Q4 '25 | 2025-12-31 | $17.10M | $5.64M | $0.48 | $-2.38M |
| Q3 '25 | 2025-09-30 | $6.99M | $-6.65M | $-0.62 | $-3.82M |
| Q2 '25 | 2025-06-30 | $9.03M | $-5.32M | $-0.57 | $-3.04M |
| Q1 '25 | 2025-03-31 | $8.59M | $-4.20M | $-0.47 | $-4.12M |
| Q4 '24 | 2024-12-31 | $12.56M | $-1.40M | $0.17 | $-1.02M |
| Q3 '24 | 2024-09-30 | $9.01M | $-5.67M | $-0.98 | $-1.21M |
| Q2 '24 | 2024-06-30 | $7.84M | $-257.00K | $-0.05 | $-4.72M |
| Q1 '24 | 2024-03-31 | $7.91M | $-10.44M | $-2.88 | $-3.33M |
| Q4 '23 | 2023-12-31 | $10.60M | $3.53M | $4.55 | $-8.77M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
BFRI vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.23T | 43.9 | +45.5% | +25.2% | 36 |
| JNJ Johnson & Johnson | $656.5B | 40.5 | +7.8% | +28.8% | 100 |
| ABBV ABBVIE INC. | $505.6B | 48.8 | +10.7% | +23.7% | 47 |
| MRK Merck & Co., Inc. | $339.7B | 137.1 | +4.9% | +24.9% | 54 |
| NVS Novartis AG | $293.1B | — | — | +9.3% | 29 |
| AZN AstraZeneca PLC | $277.2B | — | — | +91.5% | 20 |
| ABT Abbott Laboratories | $181.0B | 38.6 | +10.0% | −16.1% | 32 |
| NVO Novo-Nordisk A/S | $173.8B | — | — | −25.7% | 25 |
| BFRI Biofrontera Inc. Common Stock | $11M | — | +29.8% | −19.4% | — |
| Peer median | $316.4B | 43.9 | +10.0% | +24.3% | 34 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.